Economical aspect and possible barriers: - Industry perspectiveWritten by Geoffrey McDonough
Dr. Geoffrey McDonough is President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi). He joined Sobi in August 2011 from Genzyme Corporation, where he held a variety of senior positions over a nine year period. Most recently Dr. McDonough was President of Genzyme Europe, responsible for a $1.8B USD portfolio composed of 17 products, 55 countries and 1500 employees across Europe, Eurasia/Russia, Middle East, Africa, and Commonwealth countries. Prior to his role as President of Genzyme Europe, Dr. McDonough held the position of Senior Vice President and General Manager of Genzyme‚Äôs Personalized Genetic Health division, in which he was responsible for a $2.2B USD portfolio composed of four biological products. Dr. McDonough has also held senior positions, including Senior Vice President and Global Business Unit Leader within Genzyme‚Äôs LSD Therapeutics business, during which time he played a central role in the consolidation of European and US‚Äźbased commercial organizations to a global structure and in the successful launch of Myozyme for Pompe disease. Prior to joining Genzyme, Dr. McDonough was a paediatrician and internist at Massachusetts General Hospital in Boston. In 1999 he co‚Äźfounded Catalyst Medical Solutions Inc., a clinical documentation and coding company. Dr. McDonough has a B.Sc. in Biology and a B.A. in Philosophy from University of North Carolina at Chapel Hill, graduating summa cum laude in both. He obtained an M.D. at Harvard Medical School.